At a glance
ClinicalIndex Comparison RecordN/ARecruiting· 11,625 target
Drug / intervention
EBV antibodies test +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT05447169N/ARecruitingUpdate OverdueUpdated 47mo ago · Completion was 12mo agoEnrollment Stalled
Long Recruiting
Update Overdue
Parallel Controlled Study of Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening in the High-risk Population
In Brief
An observational study evaluating EBV antibodies test and EBV DNA test for Nasopharyngeal Carcinoma. Currently recruiting, targeting 11,625 participants across 1 site.
Signals
Enrollment appears stalled
Detailed Summary
The investigators intend to compare Epstein-Barr virus antibody and Epstein-Barr virus DNA screening efficacy in first-degree relatives of nasopharyngeal carcinoma patients.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNasopharyngeal Carcinoma
CountriesChina
Timeline
N/ARecruiting
20232024202520262027202820292030
First PostedJul 2022
Enrollment StartJul 2022
Primary CompletionJul 2025
TodayJul 2026
Study CompletionJul 2030
First PostedJul 7, 2022
Enrollment StartJul 10, 2022
Primary CompletionJul 1, 2025
Study CompletionJul 1, 2030
TodayJul 1, 2026
Enrollment to primary: 3.0 yearsPosted 4.0 years ago
Interventions
EBV antibodies testother
ELISA test of VCA-IgA，EBNA1-IgA，EA-IgA， Zta-IgA ，Rta-IgG and BNLF 2b in nasopharyngeal brushing and plasma
EBV DNA testother
quantitative polymerase chain reaction, CRISPR-associated protein 12a and target sequencing of EBV DNA in nasopharyngeal brushing and plasma